Literature DB >> 24127605

Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.

Jeremy P Wood1, Matthew W Bunce, Susan A Maroney, Paula B Tracy, Rodney M Camire, Alan E Mast.   

Abstract

Tissue factor (TF) pathway inhibitor (TFPI) is a well-characterized activated factor X (FXa)-dependent inhibitor of TF-initiated coagulation produced in two alternatively spliced isoforms, TFPIα and TFPIβ. The TFPIα C terminus has a basic sequence nearly identical to a portion of the factor V (FV) B domain necessary for maintaining FV in an inactive conformation via interaction with an acidic region of the B domain. We demonstrate rapid inhibition of prothrombinase by TFPIα mediated through a high-affinity exosite interaction between the basic region of TFPIα and the FV acidic region, which is retained in FXa-activated FVa and platelet FVa. This inhibitory activity is not mediated by TFPIβ and is lost upon removal of the acidic region of FVa by thrombin. The data identify a previously undescribed, isoform-specific anticoagulant function for TFPIα and are a unique description of physiologically relevant inhibition of prothrombinase. These findings, combined with previous descriptions of differential expression patterns of TFPIα and TFPIβ in platelets and endothelial cells, suggest that the TFPI isoforms may act through distinct mechanisms to inhibit the initial stages of intravascular coagulation, with TFPIβ acting to dampen TF expressed on the surface of vascular cells, whereas TFPIα dampens the initial prothrombinase formed on the activated platelet surface.

Entities:  

Keywords:  bleeding; hemophilia; thrombosis

Mesh:

Substances:

Year:  2013        PMID: 24127605      PMCID: PMC3816478          DOI: 10.1073/pnas.1310444110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  Clustal W and Clustal X version 2.0.

Authors:  M A Larkin; G Blackshields; N P Brown; R Chenna; P A McGettigan; H McWilliam; F Valentin; I M Wallace; A Wilm; R Lopez; J D Thompson; T J Gibson; D G Higgins
Journal:  Bioinformatics       Date:  2007-09-10       Impact factor: 6.937

Review 2.  Surface-dependent reactions of the vitamin K-dependent enzyme complexes.

Authors:  K G Mann; M E Nesheim; W R Church; P Haley; S Krishnaswamy
Journal:  Blood       Date:  1990-07-01       Impact factor: 22.113

3.  Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor.

Authors:  R J Baugh; G J Broze; S Krishnaswamy
Journal:  J Biol Chem       Date:  1998-02-20       Impact factor: 5.157

4.  The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va.

Authors:  M Ndonwi; T J Girard; G J Broze
Journal:  J Thromb Haemost       Date:  2012-09       Impact factor: 5.824

5.  Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.

Authors:  M E Gorczyca; S C Nair; B Jilma; S Priya; C Male; S Reitter; P Knoebl; J C Gilbert; R G Schaub; M Dockal; K E McGinness; I Pabinger; A Srivastava
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

6.  Deficiency of factor Xa-factor Va binding sites on the platelets of a patient with a bleeding disorder.

Authors:  J P Miletich; W H Kane; S L Hofmann; N Stanford; P W Majerus
Journal:  Blood       Date:  1979-11       Impact factor: 22.113

7.  Heterogeneity of plasma tissue factor pathway inhibitor.

Authors:  G J Broze; G W Lange; K L Duffin; L MacPhail
Journal:  Blood Coagul Fibrinolysis       Date:  1994-08       Impact factor: 1.276

8.  Activation of human factor V by factor Xa and thrombin.

Authors:  D D Monkovic; P B Tracy
Journal:  Biochemistry       Date:  1990-02-06       Impact factor: 3.162

9.  Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va.

Authors:  Sinh Tran; Eva Norstrøm; Björn Dahlbäck
Journal:  J Biol Chem       Date:  2008-01-15       Impact factor: 5.157

10.  Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα.

Authors:  Lisa M Vincent; Sinh Tran; Ruzica Livaja; Tracy A Bensend; Dianna M Milewicz; Björn Dahlbäck
Journal:  J Clin Invest       Date:  2013-08-27       Impact factor: 14.808

View more
  64 in total

1.  2013 scientific sessions Sol Sherry distinguished lecture in thrombosis: polyphosphate: a novel modulator of hemostasis and thrombosis.

Authors:  Stephanie A Smith; James H Morrissey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-23       Impact factor: 8.311

2.  Occlusion of anion-binding exosite 2 in meizothrombin explains its impaired ability to activate factor V.

Authors:  Harlan N Bradford; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2018-12-21       Impact factor: 5.157

3.  Platelets contain tissue factor pathway inhibitor-2 derived from megakaryocytes and inhibits fibrinolysis.

Authors:  Kanagasabai Vadivel; Sathya-Moorthy Ponnuraj; Yogesh Kumar; Anne K Zaiss; Matthew W Bunce; Rodney M Camire; Ling Wu; Denis Evseenko; Harvey R Herschman; Madhu S Bajaj; S Paul Bajaj
Journal:  J Biol Chem       Date:  2014-09-28       Impact factor: 5.157

4.  Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism.

Authors:  J Dennis; V Truong; D Aïssi; A Medina-Rivera; S Blankenberg; M Germain; M Lemire; L Antounians; M Civelek; R Schnabel; P Wells; M D Wilson; P-E Morange; D-A Trégouët; F Gagnon
Journal:  J Thromb Haemost       Date:  2016-09-17       Impact factor: 5.824

5.  A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A.

Authors:  Kathryn G Link; Michael T Stobb; Matthew G Sorrells; Maria Bortot; Katherine Ruegg; Marilyn J Manco-Johnson; Jorge A Di Paola; Suzanne S Sindi; Aaron L Fogelson; Karin Leiderman; Keith B Neeves
Journal:  J Thromb Haemost       Date:  2019-11-01       Impact factor: 5.824

6.  Interaction of factor V B-domain acidic region with its basic region and with TFPI/TFPI2: Structural insights from molecular modeling studies.

Authors:  Kanagasabai Vadivel; Yogesh Kumar; Matthew W Bunce; Rodney M Camire; Madhu S Bajaj; S Paul Bajaj
Journal:  Int Biol Rev       Date:  2017-05

Review 7.  Polyphosphate as modulator of hemostasis, thrombosis, and inflammation.

Authors:  J H Morrissey; S A Smith
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

8.  Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.

Authors:  Yuichi Kamikubo; G Loredana Mendolicchio; Antonella Zampolli; Patrizia Marchese; Andrea S Rothmeier; Jennifer Nagrampa Orje; Andrew J Gale; Sriram Krishnaswamy; András Gruber; Henrik Østergaard; Lars C Petersen; Wolfram Ruf; Zaverio M Ruggeri
Journal:  Blood       Date:  2017-07-20       Impact factor: 22.113

9.  Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys.

Authors:  Jian-Ming Gu; Xiao-Yan Zhao; Thomas Schwarz; Joachim Schuhmacher; Andreas Baumann; Elena Ho; Babu Subramanyan; Kathy Tran; Timothy Myles; Chandra Patel; Maria Koellnberger
Journal:  AAPS J       Date:  2017-05-17       Impact factor: 4.009

10.  A Pilot Study Using a Multistaged Integrated Analysis of Gene Expression and Methylation to Evaluate Mechanisms for Evening Fatigue in Women Who Received Chemotherapy for Breast Cancer.

Authors:  Elena Flowers; Annesa Flentje; Jon Levine; Adam Olshen; Marilyn Hammer; Steven Paul; Yvette Conley; Christine Miaskowski; Kord M Kober
Journal:  Biol Res Nurs       Date:  2019-01-31       Impact factor: 2.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.